Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
Thymic carcinoma is a relatively rare and aggressive thymic epithelial tumor. Herein, we report successful treatment of thymic carcinoma with pembrolizumab. A 68-year-old woman was admitted to our hospital for evaluation of chest pain. Chest computed tomography showed a mass in the anterior mediasti...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2018-10-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/493187 |
| _version_ | 1811262717829316608 |
|---|---|
| author | Takuma Isshiki Kazutoshi Isobe Naobumi Tochigi Motoko Sunakawa Yasuhiko Nakamura Kazutoshi Shibuya Susumu Sakamoto Yujiro Takai Sakae Homma |
| author_facet | Takuma Isshiki Kazutoshi Isobe Naobumi Tochigi Motoko Sunakawa Yasuhiko Nakamura Kazutoshi Shibuya Susumu Sakamoto Yujiro Takai Sakae Homma |
| author_sort | Takuma Isshiki |
| collection | DOAJ |
| description | Thymic carcinoma is a relatively rare and aggressive thymic epithelial tumor. Herein, we report successful treatment of thymic carcinoma with pembrolizumab. A 68-year-old woman was admitted to our hospital for evaluation of chest pain. Chest computed tomography showed a mass in the anterior mediastinum and lymphadenopathy in the left cervical lymph node. Analysis of biopsy specimens detected squamous cell carcinoma in the left cervical lymph node, and immunohistochemical analysis showed 100% expression of programmed death-ligand 1 (PD-L1). Masaoka-Koga stage IVb thymic carcinoma was ultimately diagnosed. Since 3 cycles of first-line chemotherapy did not result in improvement, pembrolizumab was administered as second-line treatment every 3 weeks at a dosage of 200 mg. After 3 cycles of pembrolizumab treatment, the size of the anterior mediastinal tumor and metastatic lesions had notably decreased. Pembrolizumab may prove to be an effective therapy for thymic carcinoma with high PD-L1 expression. |
| first_indexed | 2024-04-12T19:31:57Z |
| format | Article |
| id | doaj.art-4f38fe955eb246508672c9db4234530f |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-12T19:31:57Z |
| publishDate | 2018-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-4f38fe955eb246508672c9db4234530f2022-12-22T03:19:20ZengKarger PublishersCase Reports in Oncology1662-65752018-10-0111368869210.1159/000493187493187Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 ExpressionTakuma IsshikiKazutoshi IsobeNaobumi TochigiMotoko SunakawaYasuhiko NakamuraKazutoshi ShibuyaSusumu SakamotoYujiro TakaiSakae HommaThymic carcinoma is a relatively rare and aggressive thymic epithelial tumor. Herein, we report successful treatment of thymic carcinoma with pembrolizumab. A 68-year-old woman was admitted to our hospital for evaluation of chest pain. Chest computed tomography showed a mass in the anterior mediastinum and lymphadenopathy in the left cervical lymph node. Analysis of biopsy specimens detected squamous cell carcinoma in the left cervical lymph node, and immunohistochemical analysis showed 100% expression of programmed death-ligand 1 (PD-L1). Masaoka-Koga stage IVb thymic carcinoma was ultimately diagnosed. Since 3 cycles of first-line chemotherapy did not result in improvement, pembrolizumab was administered as second-line treatment every 3 weeks at a dosage of 200 mg. After 3 cycles of pembrolizumab treatment, the size of the anterior mediastinal tumor and metastatic lesions had notably decreased. Pembrolizumab may prove to be an effective therapy for thymic carcinoma with high PD-L1 expression.https://www.karger.com/Article/FullText/493187PembrolizumabPD-1PD-L1Thymic carcinoma |
| spellingShingle | Takuma Isshiki Kazutoshi Isobe Naobumi Tochigi Motoko Sunakawa Yasuhiko Nakamura Kazutoshi Shibuya Susumu Sakamoto Yujiro Takai Sakae Homma Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression Case Reports in Oncology Pembrolizumab PD-1 PD-L1 Thymic carcinoma |
| title | Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression |
| title_full | Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression |
| title_fullStr | Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression |
| title_full_unstemmed | Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression |
| title_short | Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression |
| title_sort | successful use of pembrolizumab to treat refractory thymic carcinoma with high pd l1 expression |
| topic | Pembrolizumab PD-1 PD-L1 Thymic carcinoma |
| url | https://www.karger.com/Article/FullText/493187 |
| work_keys_str_mv | AT takumaisshiki successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression AT kazutoshiisobe successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression AT naobumitochigi successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression AT motokosunakawa successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression AT yasuhikonakamura successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression AT kazutoshishibuya successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression AT susumusakamoto successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression AT yujirotakai successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression AT sakaehomma successfuluseofpembrolizumabtotreatrefractorythymiccarcinomawithhighpdl1expression |